These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8658396)

  • 1. [Quality adjusted life years in assessment of preventive measures. Should blood donors be tested for HTLV-I/II infections?].
    Magnus P; Stigum H; Nord E; Bjørndal A; Samdal HH; Skulberg A; Heier HE
    Tidsskr Nor Laegeforen; 1996 Apr; 116(10):1229-32. PubMed ID: 8658396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model.
    Stigum H; Magnus P; Samdal HH; Nord E
    Int J Epidemiol; 2000 Dec; 29(6):1076-84. PubMed ID: 11101551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
    Blejer JL; Saguier MC; Salamone HJ; Carreras LA
    Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood safety strategies for human T-cell lymphotropic virus in Europe.
    Laperche S; Worms B; Pillonel J; ;
    Vox Sang; 2009 Feb; 96(2):104-10. PubMed ID: 19076337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human T-lymphotropic virus infection: is it a threat?
    Zaaijer H
    Transplant Proc; 1996 Oct; 28(5):2940. PubMed ID: 8908133
    [No Abstract]   [Full Text] [Related]  

  • 6. Human T-lymphotropic virus and transfusion safety: does one size fit all?
    Marano G; Vaglio S; Pupella S; Facco G; Catalano L; Piccinini V; Liumbruno GM; Grazzini G
    Transfusion; 2016 Jan; 56(1):249-60. PubMed ID: 26388300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of human T-lymphotropic virus type I and type II antibody among blood donors in Eastern Saudi Arabia.
    Ul-Hassan Z; Al-Bahrani AT; Panhotra BR
    Saudi Med J; 2004 Oct; 25(10):1419-22. PubMed ID: 15494814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HTLV examination of Norwegian blood donors].
    Samdal HH; Skaug K; Stigum H; Hervig T; Kjeldsen-Kragh J; Skar AG
    Tidsskr Nor Laegeforen; 1999 Jan; 119(2):206-8. PubMed ID: 10081351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HTLV-I/II infection in blood donors in Buenos Aires.
    Gutfraind Z; Blejer JL; Saguier MC; Gómez Carretero ML; Pirola DA; Carreras Vescio LA
    Medicina (B Aires); 1995; 55(4):295-9. PubMed ID: 8728867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of antibodies to human T-lymphotropic viruses types I and II among healthy blood donors.
    Taha MA; Bashawri LA; Ahmed MS; Ahmed MA
    Saudi Med J; 2003 Jun; 24(6):637-40. PubMed ID: 12847594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004.
    Stramer SL; Foster GA; Dodd RY
    Transfusion; 2006 May; 46(5):703-7. PubMed ID: 16686837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia.
    El-Hazmi MM
    Saudi Med J; 2004 Jan; 25(1):26-33. PubMed ID: 14758374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening blood donors for HTLV-1: a case for a cost-benefit analysis.
    West Indian Med J; 1990 Sep; 39(3):195-6. PubMed ID: 2124755
    [No Abstract]   [Full Text] [Related]  

  • 15. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil.
    Namen-Lopes MS; Martins ML; Drummond PC; Lobato RR; ; Carneiro-Proietti AB
    Transfus Med; 2009 Aug; 19(4):180-8. PubMed ID: 19706135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is seroprevalence of HTLV-I/II among blood donors in Lebanon relevant?
    Tamim H; Musharrafieh U; Ramia S; Almawi WY; Al-Jisr T; Ayoub T; Nabulsi-Majzoub M; Kazma H; Baz EK
    Am J Infect Control; 2004 Jun; 32(4):220-3. PubMed ID: 15175617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T-cell lymphotropic virus type I and II in transfusion medicine.
    Sandler SG; Fang CT; Williams AE
    Transfus Med Rev; 1991 Apr; 5(2):93-107. PubMed ID: 1687974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States.
    Murphy EL; Watanabe K; Nass CC; Ownby H; Williams A; Nemo G
    J Infect Dis; 1999 Dec; 180(6):1777-83. PubMed ID: 10558931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infection with T-lymphotropic virus in Dutch blood donors, 1993-1996].
    Zaaijer HL; Lelie PN; van der Poel CL
    Ned Tijdschr Geneeskd; 1997 Aug; 141(32):1571-2. PubMed ID: 9543753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of human T-cell leukemia virus types I and II in Switzerland.
    Böni J; Bisset LR; Burckhardt JJ; Joller-Jemelka HI; Bürgisser P; Perrin L; Gorgievski M; Erb P; Fierz W; Piffaretti JC; Schüpbach J;
    J Med Virol; 2004 Feb; 72(2):328-37. PubMed ID: 14695678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.